
Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Date | Quarter | Revenue Forecast | Actual Revenue | Reported EPS | Consensus EPS | Beat/Miss |
---|---|---|---|---|---|---|
09/30/2025 | Q3 | $159.2M | -- | -- | $0.19 | -- |
08/07/2025 | Q2 | $145.5M | -- | -- | $0.06 | -- |
05/06/2025 | Q1 | $165.1M | $162M | -$1.59 | $0.19 | -$1.78 |
02/04/2025 | Q4 | $165M | $166.1M | $1.51 | $0.28 | $1.23 |
11/13/2024 | Q3 | $180.3M | $181.3M | $0.22 | $0.35 | -$0.13 |
08/07/2024 | Q2 | $180.1M | $181.7M | $0.22 | $0.30 | -$0.08 |
05/01/2024 | Q1 | $174.2M | $172.1M | -$1.83 | $0.24 | -$2.07 |
01/31/2024 | Q4 | $172M | $171.2M | $0.16 | $0.26 | -$0.10 |
11/15/2023 | Q3 | $200.2M | $202.3M | $0.41 | $0.43 | -$0.02 |
08/08/2023 | Q2 | $190.1M | $190.9M | $0.07 | $0.32 | -$0.25 |
05/03/2023 | Q1 | -- | $173M | $0.26 | -- | -- |
02/01/2023 | Q4 | -- | $176.2M | $0.25 | -- | -- |
11/16/2022 | Q3 | -- | $286.3M | $1.10 | -- | -- |
08/03/2022 | Q2 | -- | $372.1M | $1.99 | -- | -- |
05/04/2022 | Q1 | -- | $384.3M | $1.86 | -- | -- |
02/02/2022 | Q4 | -- | $460.9M | $2.11 | -- | -- |
11/17/2021 | Q3 | -- | $485.3M | $2.10 | -- | -- |
08/04/2021 | Q2 | -- | $424.3M | $1.79 | -- | -- |
05/05/2021 | Q1 | -- | $340.2M | $1.13 | -- | -- |
02/03/2021 | Q4 | -- | $267.9M | $0.77 | -- | -- |
11/19/2020 | Q3 | -- | $177.7M | $0.25 | -- | -- |
07/29/2020 | Q2 | -- | $150.5M | $0.18 | -- | -- |
04/29/2020 | Q1 | -- | $150.7M | $0.19 | -- | -- |
01/29/2020 | Q4 | -- | $144.3M | $0.21 | -- | -- |
11/14/2019 | Q3 | -- | $139.8M | $0.10 | -- | -- |
08/01/2019 | Q2 | -- | $127.1M | $0.02 | -- | -- |
05/02/2019 | Q1 | -- | $115.9M | -$0.05 | -- | -- |
01/31/2019 | Q4 | -- | $157.2M | $0.11 | -- | -- |
11/19/2018 | Q3 | -- | $184.8M | $0.43 | -- | -- |
08/01/2018 | Q2 | -- | $268.8M | $0.86 | -- | -- |
05/02/2018 | Q1 | -- | $221.8M | $0.51 | -- | -- |
01/31/2018 | Q4 | -- | $213.7M | -$0.99 | -- | -- |
11/14/2017 | Q3 | -- | $215.9M | $0.51 | -- | -- |
08/02/2017 | Q2 | -- | $243.9M | $0.48 | -- | -- |
05/03/2017 | Q1 | -- | $199.6M | $0.45 | -- | -- |
02/02/2017 | Q4 | -- | $149.6M | $0.24 | -- | -- |
11/15/2016 | Q3 | -- | $145.8M | $0.15 | -- | -- |
08/03/2016 | Q2 | -- | $216.4M | $0.45 | -- | -- |
05/04/2016 | Q1 | -- | $156.4M | $0.07 | -- | -- |
02/03/2016 | Q4 | -- | $108.5M | -$0.00 | -- | -- |
11/17/2015 | Q3 | -- | $119.2M | $0.13 | -- | -- |
Kulicke & Soffa Industries reported $162M worth of top line sales in its most recent quarter.
Kulicke & Soffa Industries announced earnings per share of -$1.59 which represents a miss of analyst forecast a $0.19 per share.
Kulicke & Soffa Industries reported $40.4M that represents $0.76 per share over the last quarter.
Kulicke & Soffa Industries's earnings are forecast to decrease from -$1.24 per share to $0.04 per share next year representing a decrease of -95.71%.
Kulicke & Soffa Industries's next earnings date is August 7, 2025.
Signup to receive the latest stock alerts
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Market Cap: $4.2T
P/E Ratio: 58x
Market Cap: $3.8T
P/E Ratio: 43x
Market Cap: $3.1T
P/E Ratio: 35x
SharpLink Gaming [SBET] is down 2.6% over the past day.
Exodus Movement [EXOD] is down 4.14% over the past day.
Unity Software [U] is up 7.51% over the past day.